SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue, signaling continued momentum for its SSi Mantra surgical robotic platform. The company, a developer of innovative surgical robotic technologies, announced revenue of $13.9 million for the quarter, a 39.4% increase from $10.0 million in the same period last year. This growth reflects strong demand for the SSi Mantra system, with installations rising 30.4% to 30 systems during the quarter. The installed base now stands at 224 systems across 12 countries, with 12,272 cumulative surgeries performed to date.
The company's first-half performance was equally robust, with revenue reaching $25.0 million, a 65.6% increase from $15.1 million in the first half of 2025. Gross profit for the first half increased 77.5% to $12.4 million, although the gross margin for the quarter declined to 50.9% from 59.1% in the year-earlier quarter (https://nnw.fm/zxrT1). This margin pressure may reflect increased costs associated with scaling production and expanding the installed base.
Beyond financial metrics, SS Innovations is making strategic strides in regulatory approvals. The company is targeting U.S. Food and Drug Administration (FDA) clearance by the first quarter of 2027 and European CE marking by the end of 2026. These milestones are critical catalysts that could open up the world's largest healthcare markets for the SSi Mantra system. The company's telesurgery achievements are also extending the clinical profile of the platform, demonstrating its capabilities beyond traditional surgical settings.
The growth in installations remains the primary commercial driver for SS Innovations. Each new system represents a recurring revenue stream through service contracts and instrument sales, and the expanding installed base enhances the company's footprint in the competitive surgical robotics market. The SSi Mantra platform is designed to make robotic surgery more accessible, potentially addressing a broader range of procedures and patient populations.
The company's performance comes at a time when the global surgical robotics market is projected to grow significantly, driven by technological advancements and increasing adoption of minimally invasive procedures. SS Innovations' focus on innovation and expansion positions it well to capitalize on these trends. With a strong first half and strategic regulatory targets on the horizon, the company is poised for continued growth.
Investors and industry observers will be watching closely as SS Innovations navigates the regulatory landscape and works to expand its market presence. The company's ability to execute on its growth strategy will be key to its long-term success in the evolving healthcare technology sector.
